These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 14731351)
1. [Progress in the clinical use of anti-arrhythmic drugs (I)]. Li WZ Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351 [No Abstract] [Full Text] [Related]
3. New antiarrhythmic drugs for the treatment of atrial fibrillation. Castro A; Bianconi L; Santini M Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001 [No Abstract] [Full Text] [Related]
4. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias. Reiffel JA J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635 [No Abstract] [Full Text] [Related]
5. Clinical differences between the newer antiarrhythmic agents. Camm AJ Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520 [TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of ventricular arrhythmias - a contemporary perspective]. Grönefeld GC; Hohnloser SH Dtsch Med Wochenschr; 2002 Oct; 127(43):2280-4. PubMed ID: 12397544 [No Abstract] [Full Text] [Related]
7. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
8. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
10. Pure class III agents for prevention of sudden cardiac death. Pratt CM J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526 [TBL] [Abstract][Full Text] [Related]
11. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. Singh S J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742 [TBL] [Abstract][Full Text] [Related]
12. [Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent]. Z Kardiol; 1999 Oct; 88(10 Suppl):1-2. PubMed ID: 10586493 [No Abstract] [Full Text] [Related]
13. [The research practice of anti-arrhythmic agents targeting on potassium ion channel]. Yang Q; Wang XJ; Tang YQ; You QD Yao Xue Xue Bao; 2011 Jan; 46(1):12-8. PubMed ID: 21465803 [TBL] [Abstract][Full Text] [Related]
14. Oral class III antiarrhythmics: what is new? Khan MH Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634 [TBL] [Abstract][Full Text] [Related]
15. Azimilide. NE 10064, Stedicor. Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048 [No Abstract] [Full Text] [Related]
16. A benefit-risk assessment of class III antiarrhythmic agents. Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415 [TBL] [Abstract][Full Text] [Related]
17. Azimilide dihydrochloride: a unique class III antiarrhythmic agent. Tran HT Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612 [TBL] [Abstract][Full Text] [Related]
19. Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Abrol R; Page RL Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832 [TBL] [Abstract][Full Text] [Related]
20. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling. Vos MA; Crijns HJ Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]